DMAC · DiaMedica Therapeutics Inc

-

Please sign in to comment on DMAC

1 Comment

Admin

3 years, 7 months ago

DiaMedica Therapeutics Inc is currently in a long term downtrend where the price is trading 45.6% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

DiaMedica Therapeutics Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has dropped by 69.4% to $-4M since the same quarter in the previous year.

Finally, its free cash flow fell by 64.0% to $-3M since the same quarter in the previous year.

Based on the above factors, DiaMedica Therapeutics Inc gets an overall score of 1/5.

Industry	Biotechnology
Sector	Healthcare
CurrencyCode	USD
Exchange	NASDAQ
ISIN	CA25253X2077

PE Ratio	None
Market Cap	45M
Beta	1.7
Dividend Yield	0.0%
Target Price	7.5

ABOUT

DiaMedica Therapeutics Inc

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

DMAC · DiaMedica Therapeutics Inc

-

DiaMedica Therapeutics Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest DiaMedica Therapeutics Inc using a moving average strategy